Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Predictions

buy
Protalix Biotherapeutics Inc.

Start price
Target price
Perf. (%)
€5.10
19.04.21
-
19.04.22
-76.52%
20.04.22

Could be very worthwhile Investment >20% year
buy
Xinyi Solar Holdings Ltd

Start price
Target price
Perf. (%)
€1.49
19.04.21
€2.00
19.04.22
0.73%
20.04.22

Could be very worthwhile Investment >20% year
Higher EBIT margin than peer group
Fair valuation
Standard Investments for future growth
buy
Play Magnus As

Start price
Target price
Perf. (%)
€2.16
19.04.21
€3.00
19.04.22
-42.69%
20.04.22

Could be worthwhile Investment >10% per year
Revenue growth >5% per year expected
positive Cash Flow expected
Good rating
buy
Moderna Inc.

Start price
Target price
Perf. (%)
€158.84
04.04.22
€178.00
04.04.23
-12.49%
19.04.22

Revenue growth >5% per year expected
Differentiated customer and product portfolio
Future proof or reliable business model
Higher risks for its business
buy
2G Energy AG

Start price
Target price
Perf. (%)
€123.80
06.04.22
€140.00
06.04.23
-3.07%
19.04.22

Top 10 in its market
Revenue growth >5% per year expected
Sustainability is very important
Significant cyclical dependencies
Endeavour Silver Corp.

Start price
Target price
Perf. (%)
€3.93
24.02.22
-
24.02.23
24.62%
19.04.22

Probably not worthwhile Investment
buy
Nine Energy Service Inc.

Start price
Target price
Perf. (%)
€3.12
04.04.22
€6.50
04.04.23
-11.15%
19.04.22

Could be very worthwhile Investment >20% year
buy
Newegg Commerce Inc.

Start price
Target price
Perf. (%)
€6.20
05.04.22
€11.50
05.04.23
-4.03%
19.04.22

Could be very worthwhile Investment >20% year
K+S AG

Start price
Target price
Perf. (%)
€34.30
13.04.22
€30.00
13.04.23
3.18%
19.04.22

Risky Investment
buy
Windeln.de SE

Start price
Target price
Perf. (%)
€1.20
14.04.22
-
14.04.23
5.00%
19.04.22

Risky Investment
buy
Tesla Inc

Start price
Target price
Perf. (%)
€197.53
18.08.21
€220.00
18.08.22
59.20%
19.04.22

Could be worthwhile Investment >10% per year
Revenue growth >5% per year expected
buy
Electro-Sensors Inc

Start price
Target price
Perf. (%)
€3.42
18.04.21
€4.00
18.04.22
25.73%
19.04.22

Could be worthwhile Investment >10% per year
buy
Energous Corp.

Start price
Target price
Perf. (%)
€2.70
18.04.21
€3.50
18.04.22
-64.01%
19.04.22

Could be worthwhile Investment >10% per year
buy
China Tian Lun Gas Holding

Start price
Target price
Perf. (%)
€0.83
18.04.21
€9.50
18.04.22
-30.12%
19.04.22

Could be worthwhile Investment >10% per year
buy
Astrotech Corp.

Start price
Target price
Perf. (%)
€1.01
18.04.21
€2.00
18.04.22
-44.46%
19.04.22

Could be worthwhile Investment >10% per year
buy
Geo Group REIT Inc.

Start price
Target price
Perf. (%)
€4.87
18.04.21
€8.00
18.04.22
23.85%
19.04.22

Could be worthwhile Investment >10% per year
buy
Schumag AG

Start price
Target price
Perf. (%)
€1.64
18.04.21
€3.00
18.04.22
6.10%
19.04.22

Could be very worthwhile Investment >20% year
Revenue growth >5% per year expected
ROE higher than 10% per year
Very Future proof/growth oriented business model
Takung Art Co. Ltd.

Start price
Target price
Perf. (%)
€14.90
18.04.21
-
18.04.22
-83.65%
19.04.22

Probably not worthwhile Investment
BioXcel Therapeutics Inc

Start price
Target price
Perf. (%)
€19.18
04.04.22
-
04.04.23
-27.80%
18.04.22

Risky Investment
Protalix Biotherapeutics Inc.

Start price
Target price
Perf. (%)
€1.76
04.04.22
€0.000
04.04.23
-33.28%
18.04.22

EBIT decline > 20% expected
Revenue decline > 20% expected
Very low/no dividend yield expected
Sustainability is not important
Riot Blockchain Inc.

Start price
Target price
Perf. (%)
€16.30
06.04.22
€4.00
06.04.23
-13.48%
18.04.22

Little Investments for future growth
No Innovation
Significant cyclical dependencies
Very bad culture
Clovis Oncology Inc.

Start price
Target price
Perf. (%)
€2.64
06.04.22
€1.00
06.04.23
-22.00%
18.04.22

Probably not worthwhile Investment
Decining EBIT margin than peer group
overvalued
Very low/no dividend yield expected
MedAvail Holdings Inc.

Start price
Target price
Perf. (%)
€1.98
11.04.22
€0.000
11.04.23
39.39%
18.04.22

Could be worthwhile Investment >10% per year
Revenue decline/stagnation expected
EBIT decline/stagnation expected
Lower EBIT Margin than peer group
buy
Veru Inc

Start price
Target price
Perf. (%)
€12.02
11.04.22
€55.00
11.04.23
-2.33%
18.04.22

EBIT growth > 30% per year expected
Strong uniques
Very differentiated customer and product portfolio
ROE lower than 10% per year
Clovis Oncology Inc.

Start price
Target price
Perf. (%)
€2.64
06.04.22
€0.000
06.04.23
-22.00%
18.04.22

Could be worthwhile Investment >10% per year
Revenue decline > 20% expected
EBIT decline > 20% expected
Decining EBIT margin than peer group